Hirai T, Asano K, Ito I, Miyazaki Y, Sugiura H, Agirbasli M, Kobayashi S, Kobayashi M, Shimada D, Natsume I, Kawasaki T, Ohba T, Tajiri S, Sakamaki F, Mineshita M, Takihara T, Sekiya K, Tomii K, Tomioka H, Kita H, Nishizaka Y, Fukui M, Miyata T, Harigae H. A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19. Sci Rep. 2024 Jan 2;14(1):165. doi: 10.1038/s41598-023-50445-1. PMID: 38168544 Free PMC article. Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38168544/
Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, Saito T, Terui Y, Okubo S, Soshin T, Zeng J, Honda H, Badawi M, Ross JA, Izutsu K. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma. Int J Clin Oncol. 2024 Feb;29(2):232-240. doi: 10.1007/s10147-023-02443-6. Epub 2023 Dec 29.PMID: 38157190 Free PMC article. Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38157190/
Makita S, Ota S, Mishima Y, Usuki K, Ennishi D, Yanada M, Fukuhara N, Yamamoto R, Takamine A, Nohara G, Izutsu K. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Int J Hematol. 2024 Feb;119(2):156-163. doi: 10.1007/s12185-023-03689-6. Epub 2023 Dec 27. PMID: 38150138 Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38150138/
Onishi Y. Aplastic anemia: history and recent developments in diagnosis and treatment. Int J Hematol. 2024 Mar;119(3):217-219. doi: 10.1007/s12185-024-03715-1. Epub 2024 Feb 4.PMID: 38310173 https://pubmed.ncbi.nlm.nih.gov/38310173/
Imahashi N, Kurita N, Konuma T, Takahashi S, Nishida T, Tanaka M, Nakamae H, Kawakita T, Ota S, Doki N, Onishi Y, Sawa M, Ozeki K, Hiramoto N, Onizuka M, Ishimaru F, Ichinohe T, Atsuta Y, Kanda J. Effect of Conditioning Regimens and Graft-versus-Host Disease Prophylaxis on the Outcomes of Umbilical Cord Blood Transplantation Performed with Cyclophosphamide/Total Body Irradiation-Based Regimens. Transplant Cell Ther. 2024 Mar;30(3):318.e1-318.e11. doi: 10.1016/j.jtct.2023.12.004. Epub 2023 Dec 9.PMID: 38081416 https://pubmed.ncbi.nlm.nih.gov/38081416/
Onozawa M, Kusumoto S, Najima Y, Hashimoto H, Okada K, Tamaki M, Tanaka M, Sato T, Takahashi T, Hatano K, Onodera K, Moriuchi Y, Yakushijin K, Kanda J, Nagafuji K, Ogata M, Nakano N, Tamori A, Mizokami M. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study. Transplant Cell Ther. 2024 Mar;30(3):330.e1-330.e8. doi: 10.1016/j.jtct.2024.01.059. Epub 2024 Jan 17. PMID: 38242442. https://pubmed.ncbi.nlm.nih.gov/38242442/
Mitani K, Lee JW, Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Murotani K, Shimizu M, Matsuda A, Ozawa K, Nakao S. Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study. Blood Adv. 2024 Mar 26;8(6):1415-1419. doi: 10.1182/bloodadvances.2023010959. PMID: 38134300 Free PMC article. Clinical Trial. No abstract available. https://pubmed.ncbi.nlm.nih.gov/38134300/
Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, María Ferreri AJ, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan D, Ramos R, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024 Apr 25;143(17):1713-1725. doi: 10.1182/blood.2023021567. PMID: 38194692 https://pubmed.ncbi.nlm.nih.gov/38194692/
Sakurai K, Saito K, Hatta S, Katsuoka Y, Meguro K, Yokoyama H, Izumi T. Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long-term aplastic anemia treatment. Clin Case Rep. 2024 Apr 26;12(5):e8832. doi: 10.1002/ccr3.8832. eCollection 2024 May. PMID: 38681032 https://pubmed.ncbi.nlm.nih.gov/38681032/
Izutsu K, Ubukawa K, Morishita T, Onishi Y, Ishizawa K, Fujii Y, Kimura N, Yokochi M, Naoe T. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes. Cancer Sci. 2024 Apr;115(4):1250-1260. doi: 10.1111/cas.16054. Epub 2024 Feb 7. PMID: 38327103 Free PMC article. Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38327103/
Nakaya Y, Nakamae H, Nishikubo M, Kondo E, Fukuda T, Hiramoto N, Mori Y, Nagafuji K, Eto T, Onishi Y, Uchida N, Ishikawa J, Matsuoka KI, Yui S, Takase K, Kawakita T, Kanda J, Ichinohe T, Atsuta Y, Kako S. Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma. Bone Marrow Transplant. 2024 May;59(5):630-636. doi: 10.1038/s41409-024-02229-y. Epub 2024 Feb 14. PMID: 38355911 https://pubmed.ncbi.nlm.nih.gov/38355911/
Yamamoto R, Hiramoto N, Fujimoto A, Yamazaki H, Mori T, Uchida N, Doki N, Kato J, Nishikubo M, Kako S, Nishida T, Ota S, Onizuka M, Eto T, Onodera K, Ikegame K, Matsuoka KI, Kanda Y, Fukuda T, Atsuta Y, Onishi Y. Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 May;59(5):688-691. doi: 10.1038/s41409-024-02234-1. Epub 2024 Feb 10.PMID: 38341498. https://pubmed.ncbi.nlm.nih.gov/38341498/
Nakamura Y, Zaimoku Y, Yamaguchi H, Yamazaki H, Kanaya M, Uchida N, Doki N, Sakurai M, Hiramoto N, Kako S, Onizuka M, Onodera K, Maruyama Y, Ohigashi H, Nishida T, Yoshihara S, Matsuoka KI, Eto T, Kanda Y, Fukuda T, Atsuta Y, Onishi Y. Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia. Ann Hematol. 2024 Aug;103(8):3121-3133. doi: 10.1007/s00277-024-05800-1. Epub 2024 May 16. https://pubmed.ncbi.nlm.nih.gov/38750374/
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. Int J Hematol. 2024 Jul;120(1):106-116. doi: 10.1007/s12185-024-03772-6. Epub 2024 May 25. https://pubmed.ncbi.nlm.nih.gov/38796666/
Fujiwara T, Harigae H. Pyridoxine: beyond a cofactor of ALAS. Blood. 2024 Sep 26;144(13):1358-1359. doi: 10.1182/blood.2024025575. https://pubmed.ncbi.nlm.nih.gov/39325482/
Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematol. 2024 Jun;11(6):e406-e414. doi: 10.1016/S2352-3026(24)00102-9. PMID: 38796193 Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38796193/
Nakamura Y, Zaimoku Y, Yamaguchi H, Yamazaki H, Kanaya M, Uchida N, Doki N, Sakurai M, Hiramoto N, Kako S, Onizuka M, Onodera K, Maruyama Y, Ohigashi H, Nishida T, Yoshihara S, Matsuoka KI, Eto T, Kanda Y, Fukuda T, Atsuta Y, Onishi Y. Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia. Ann Hematol. 2024 Aug;103(8):3121-3133. doi: 10.1007/s00277-024-05800-1. Epub 2024 May 16. PMID: 38750374 https://pubmed.ncbi.nlm.nih.gov/38750374/
Yamaguchi M, Fukuhara N, Takizawa J, Ishitsuka K, Yokohama A, Miyazaki K, Nato Y, Ichikawa S, Mitobe M, Shima K, Miyazawa Y, Izutsu K, Suzuki R, Nagai H, Nakamura N. Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan. J Clin Exp Hematop. 2024 Sep 28;64(3):216-222. doi: 10.3960/jslrt.24028. Epub 2024 Jul 2. PMID: 38960696 Free PMC article. https://pubmed.ncbi.nlm.nih.gov/38960696/
Oyake T, Maeta T, Takahata T, Tamai Y, Kameoka Y, Takahashi N, Miyairi Y, Murai K, Shimosegawa K, Yoshida K, Inokura K, Fukuhara N, Harigae H, Sato R, Ishizawa K, Tajima K, Saitou S, Fukatsu M, Ikezoe T, Tsunoda S, Mita M, Mori J, Kowata S, Ito S. Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin's lymphoma. J Clin Exp Hematop. 2024 Sep 28;64(3):191-202. doi: 10.3960/jslrt.24021. Epub 2024 Jul 31. PMID: 39085129 Free PMC article. https://pubmed.ncbi.nlm.nih.gov/39085129/
Kusumoto S, Munakata W, Machida R, Terauchi T, Onaya H, Oguchi M, Iida S, Nosaka K, Suzuki Y, Harada Y, Miyazaki K, Maruta M, Fukuhara N, Toubai T, Kubota N, Ohmachi K, Saito T, Rai S, Mizuno I, Fukuhara S, Takeuchi M, Tateishi U, Maruyama D, Tsukasaki K, Nagai H. Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305). Cancer Sci. 2024 Oct;115(10):3384-3393. doi: 10.1111/cas.16281. Epub 2024 Jul 22. PMID: 39034771 Free PMC article. https://pubmed.ncbi.nlm.nih.gov/39034771/
Kawajiri A, Li J, Koinuma K, Yang Z, Yoon HJ, Yi J, Nagashima H, Ishii M, Gao F, Sato K, Tayama S, Harigae H, Iwakura Y, Ishii N, Sher A, Ishigaki K, Zhu J, Kim KS, Kawabe T. Naturally arising memory-phenotype CD4+ T lymphocytes contain an undifferentiated population that can generate TH1, TH17, and Treg cells. Sci Adv. 2024 Dec 6;10(49):eadq6618. doi: 10.1126/sciadv.adq6618. Epub 2024 Dec 4. PMID: 39630890 Free PMC article https://pubmed.ncbi.nlm.nih.gov/39630890/